John Ginn

John Ginn

Auto-generated profile, based on publicly available information

John Ginn

Department of Radiation Oncology Duke Cancer Center, Duke University Durham North Carolina USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2022 in Medical Dosimetry
Verified
Journal Article
Closed access
JGJohn S. Ginn
John S. Ginn
HGHiram A. Gay
Hiram A. Gay
JHJessica Hilliard
Jessica Hilliard
JSJainil Shah
Jainil Shah
NMNilesh Mistry
Nilesh Mistry
YHYao Hao
Yao Hao

11 August 2024 in Radiotherapy and Oncology
Verified
Journal Article
Open access
ADAlden D’sOuza
Alden D’sOuza
HSHayley B. Stowe
Hayley B. Stowe
OGOlga L. Green
Olga L. Green
JSJoshua Schiff
Joshua Schiff
GHGeoffrey D. Hugo
Geoffrey D. Hugo
LHLauren E. Henke
Lauren E. Henke
A retrospective evaluation of dosimetric predictors and leveraged dose-volume data for gastrointestinal (GI) toxicities for locally-advanced pancreatic cancer (LAPC) treated with daily stereotactic MRI-guided online-adaptive radiotherapy (SMART). 147 patients with LAPC were treated with SMART at our institution between 2018 and 2021. Patients were evaluated using CTCAE V5.0 for RT-related acute (≤3 months) and late (>3 months) toxicities. Each organ at risk (OAR) was matched to a ≥ grade 2 (Gr2+) toxicity endpoint composite group. A least absolute shrinkage selector operator regression model was constructed by dose-volumes per OAR to account for OAR multicollinearity. A receiver operator curve (ROC) analysis was performed for the combined averages of significant toxicity groups to identify critical volumes per dose levels. 18 of 147 patients experienced Gr2+ GI toxicity. 17 Gr2+ duodenal toxicities were seen; the most significant predictor was a V33Gy odds ratio (OR) of 1.69 per cc (95 % CI 1.14-2.88). 17 Gr2+ small bowel (SB) toxicities were seen; the most significant predictor was a V33Gy OR of 1.60 per cc (95 % CI 1.01-2.53). The AUC was 0.72 for duodenum and SB. The optimal duodenal cut-point was 1.00 cc (true positive (TP): 17.8 %; true negative (TN); 94.9 %). The SB cut-point was 1.75 cc (TP: 16.7 %; TN: 94.3 %). No stomach or large bowel dose toxicity predictors were identified. For LAPC treated with SMART, the dose-volume threshold of V33Gy for duodenum and SB was associated with Gr2+ toxicities. These metrics can be utilized to guide future dose-volume constraints for patients undergoing upper abdominal SBRT.

3 December 2024 in Medical Physics
Verified
Journal Article
Closed access
JGJohn Ginn
John Ginn
CWChunhao Wang
Chunhao Wang
DYDeshan Yang
Deshan Yang